End-of-day quote
Shanghai S.E.
18:00:00 2024-07-02 EDT
|
5-day change
|
1st Jan Change
|
8.84
CNY
|
-1.89%
|
|
-4.12%
|
-29.56%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
5,523
|
3,366
|
2,341
|
3,655
|
-
|
-
|
Enterprise Value (EV)
1 |
5,523
|
3,366
|
2,341
|
3,655
|
3,655
|
3,655
|
P/E ratio
|
269
x
|
-24.9
x
|
-14.6
x
|
295
x
|
58.9
x
|
22.7
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
16.9
x
|
-
|
-
|
7.69
x
|
5.3
x
|
3.38
x
|
EV / Revenue
|
16.9
x
|
-
|
-
|
7.69
x
|
5.3
x
|
3.38
x
|
EV / EBITDA
|
-
|
-
|
-
|
141
x
|
40.6
x
|
17.8
x
|
EV / FCF
|
-
|
-
|
-
|
-106
x
|
-506
x
|
62.9
x
|
FCF Yield
|
-
|
-
|
-
|
-0.95%
|
-0.2%
|
1.59%
|
Price to Book
|
5.12
x
|
-
|
-
|
0.03
x
|
0.15
x
|
0.39
x
|
Nbr of stocks (in thousands)
|
410,000
|
410,000
|
410,000
|
413,456
|
-
|
-
|
Reference price
2 |
13.47
|
8.210
|
5.710
|
8.840
|
8.840
|
8.840
|
Announcement Date
|
21-02-25
|
22-02-25
|
23-02-27
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
327.4
|
-
|
-
|
475
|
689
|
1,080
|
EBITDA
1 |
-
|
-
|
-
|
26
|
90
|
205
|
EBIT
1 |
24.01
|
-
|
-
|
14
|
81
|
200
|
Operating Margin
|
7.33%
|
-
|
-
|
2.95%
|
11.76%
|
18.52%
|
Earnings before Tax (EBT)
1 |
28.84
|
-
|
-
|
14
|
80
|
201
|
Net income
1 |
22.49
|
-133.9
|
-161.7
|
11
|
63
|
159
|
Net margin
|
6.87%
|
-
|
-
|
2.32%
|
9.14%
|
14.72%
|
EPS
2 |
0.0500
|
-0.3300
|
-0.3900
|
0.0300
|
0.1500
|
0.3900
|
Free Cash Flow
1 |
-
|
-
|
-
|
-34.55
|
-7.22
|
58.14
|
FCF margin
|
-
|
-
|
-
|
-7.27%
|
-1.05%
|
5.38%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
28.36%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
36.57%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-02-25
|
22-02-25
|
23-02-27
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
-34.6
|
-7.22
|
58.1
|
ROE (net income / shareholders' equity)
|
1.93%
|
-
|
-
|
1.3%
|
7%
|
5.1%
|
ROA (Net income/ Total Assets)
|
1.75%
|
-
|
-
|
0.9%
|
5.1%
|
11.1%
|
Assets
1 |
1,287
|
-
|
-
|
1,222
|
1,235
|
1,432
|
Book Value Per Share
2 |
2.630
|
-
|
-
|
294.0
|
58.70
|
22.60
|
Cash Flow per Share
|
0.1700
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
113
|
-
|
-
|
35
|
45
|
55
|
Capex / Sales
|
34.38%
|
-
|
-
|
7.37%
|
6.53%
|
5.09%
|
Announcement Date
|
21-02-25
|
22-02-25
|
23-02-27
|
-
|
-
|
-
|
Last Close Price
8.84
CNY Average target price
12
CNY Spread / Average Target +35.75% Consensus |
1st Jan change
|
Capi.
|
---|
| -29.56% | 512M | | +10.87% | 127B | | -8.56% | 10.76B | | -21.01% | 7.06B | | +50.07% | 6.5B | | -34.16% | 3.99B | | +8.50% | 3.44B | | -20.67% | 2.45B | | -19.70% | 1.89B | | -22.48% | 1.75B |
Medical Devices & Implants
|